Highlights of the 33rd annual scientific meeting of the Association of Medical Laboratory Immunologists (AMLI).

导出 OA

翻译打印收藏纠错

第一作者： Vijaya,Knight

第一单位： Department of Pediatrics and Children's Hospital, University of Colorado School of Medicine, Aurora, CO, United States of America. Electronic address: Vijaya.Knight@childrenscolorado.org.

作者： Vijaya,Knight ^[1] ; Medhat Z,Askar ^[2] ; Evangelos,Ntrivalas ^[3] ; Sarada L,Nandiwada ^[4] ; Lisa K,Peterson ^[5] ; Anne E,Tebo ^[5] ; Kamran,Kadkhoda ^[6] ; John L,Schmitz ^[7] ; Stanley J,Naides ^[8] ; Melissa R,Snyder ^[9] ; Amir A,Sadighi Akha ^[10]

作者单位： Department of Pediatrics and Children's Hospital, University of Colorado School of Medicine, Aurora, CO, United States of America. Electronic address: Vijaya.Knight@childrenscolorado.org. ^[1] Baylor University Medical Center, Dallas, TX, United States of America. ^[2] Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. ^[3] Baylor College of Medicine and Texas Children's Hospital, Houston, TX, United States of America. ^[4] ARUP Institute for Clinical and Experimental Pathology and Department of Pathology, University of Utah Health, Salt Lake City, UT, United States of America. ^[5] Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, United States of America. ^[6] Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America. ^[7] Euroimmun US Inc., Mountain Lakes, NJ, United States of America. ^[8] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America. ^[9] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: sadighiakha.amir@mayo.edu. ^[10]

关键词 Antinuclear antibodies COVID-19 Histocompatibility Immune monitoring Immunodeficiency Immunotherapy